# Starsource Mult (NSE: STARSOURCE) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/STARSOURCE · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹14 Cr, it ranks 3762nd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Biotechnology.

Its return on equity was −39.4% in FY16. Promoters held 27.89% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹14 Cr |
| ROE | −39.4% (FY16) |
| ROCE | −38.2% (FY16) |
| Debt to equity | 0 |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | — | — | −₹0 Cr | — | −₹0.48 |
| Q3 FY26 | — | — | −₹0 Cr | — | −₹0.58 |
| Q2 FY26 | ₹1 Cr | — | ₹0 Cr | −83.6% | ₹0.65 |
| Q1 FY26 | — | — | −₹12 Cr | −4,824.0% | −₹78.70 |
| Q4 FY25 | — | — | −₹0 Cr | — | −₹2.26 |
| Q3 FY25 | — | — | −₹0 Cr | −125.0% | −₹1.17 |
| Q2 FY25 | — | — | ₹1 Cr | +38.6% | ₹4.07 |
| Q1 FY25 | — | — | ₹0 Cr | −34.2% | ₹1.64 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹0 Cr | ₹0 Cr |
| FY24 | ₹0 Cr | ₹1 Cr |
| FY23 | ₹0 Cr | ₹0 Cr |
| FY22 | ₹0 Cr | ₹1 Cr |
| FY21 | ₹0 Cr | ₹0 Cr |
| FY20 | ₹0 Cr | ₹0 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 27.89%
- Domestic institutions: 0.37%
- Non-institutions: 71.75%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Venmax Drugs](https://app.pivotnow.in/stock/VENMAX) | — | ₹17 Cr | — | — |
| [Zenith Health](https://app.pivotnow.in/stock/ZENITHHE) | — | ₹17 Cr | — | — |
| [Family Care Hos](https://app.pivotnow.in/stock/FAMILYCARE) | — | ₹16 Cr | — | — |
| [Colinz Labs](https://app.pivotnow.in/stock/COLINZ) | — | ₹15 Cr | — | — |
| [Norris Medicine](https://app.pivotnow.in/stock/NORRIS) | — | ₹14 Cr | — | — |
| [Dolphin Medical](https://app.pivotnow.in/stock/DOLPHMED) | — | ₹12 Cr | — | — |

## Questions and answers

### What is the market cap of Starsource Mult?

Starsource Mult's market capitalisation is ₹14 Cr (₹14 Cr) at the 22 Oct 2026 close, ranking 3762nd among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Starsource Mult?

Return on equity was −39.4% in FY16 and return on capital employed was −38.2% in FY16 (consolidated figures).

### Is Starsource Mult a debt-free company?

Starsource Mult is close to debt-free: its debt-to-equity ratio was 0 in FY16.

### What is the shareholding pattern of Starsource Mult?

As of 30 Jun 2026: promoters 27.89%, domestic institutions 0.37%, non-institutions 71.75%.

### Who are Starsource Mult's competitors?

The listed Pharma & Healthcare companies closest to Starsource Mult by market cap are Venmax Drugs, Zenith Health, Family Care Hos, Colinz Labs, Norris Medicine and Dolphin Medical.

### Is Starsource Mult a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Starsource Mult's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on STARSOURCE against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.